A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis ® in patients with neovascular age-related macular degeneration - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35918962/
1 Professor, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 2 Vitreo Retinal Surgeon-Department of Ophthalmology, Rising Retina Clinic, Ahmedabad, Gujarat, India. 3 Consultant, Department...
Conclusion: Lupin’s biosimilar ranibizumab demonstrated therapeutic equivalence, desirable safety, and favorable immunogenicity profile compared to Lucentis®.
Guidance on brolucizumab management recommendations
Source : https://www.sciencedirect.com/science/article/abs/pii/S2173579422000846?via=ihub
Available online 23 July 2022 Brolucizumab, a new generation anti-VEGF, has demonstrated efficacy and safety in AMD in the pivotal HAWK and HARRIER trials. Post-marketing, previously undetected adverse events related...
Conclusion: The adverse events reported are rare, but may be associated with severe and irreversible loss of visual acuity. The recommendations made are intended to facilitate the management of brolucizumab in the routine practice of retinologists, to ensure patient safety and, should any adverse events occur, to minimise their impact on...
Nicotinamide Mononucleotide Ameliorates Cellular Senescence and Inflammation Caused by Sodium Iodate in RPE
Source : https://www.hindawi.com/journals/omcl/2022/5961123/
Senescent cells have been demonstrated to have lower cellular NAD + levels and are involved in the development of various age-related diseases, including age-related macular degeneration (AMD). Sodium iodate (NaIO...
Conclusion: Our results indicate that RPE senescence induced by NaIO3 acquired several key features of AMD. More importantly, NMN may potentially be used to treat RPE senescence and senescence-associated pre-AMD changes by restoring the NAD levels in cells and tissues.
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35278204/
Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such treatments may be relatively more expensive compared to small...
Conclusion: The current review provides an introduction to biosimilars with the aim of preparing retinal specialists for discussing these products with their patients.
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence - Ophthalmology and Therapy
Source : https://link.springer.com/article/10.1007/s40123-022-00507-w
Introduction To analyze the efficacy and safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab® (Intas Pharmaceuticals, Ahmedabad, India; BRm; Razumab®) and the innovator ranibizumab drug (IRm; LUCENTIS®) in Indian...
Conclusions: Our real-world data demonstrated the ranibizumab biosimilar Razumab to have comparable visual acuity outcomes to the innovator ranibizumab molecule with an adequate safety profile in the management of PCV. Although these encouraging results support its use as a viable alternative to the innovator molecule, further prospective...